Keyphrases
Ibrutinib
100%
Toxicity Management
100%
Idelalisib
100%
B-cell Malignancies
66%
First-in-class
66%
B-cell Receptor Inhibitors
66%
Clinically Significant
33%
Elderly Patients
33%
Adverse Events
33%
Unmet Needs
33%
Relapsed Disease
33%
High Response Rate
33%
Long Progression-free Survival
33%
Chronic Lymphocytic Leukemia
33%
Immunochemotherapy
33%
Follicular Lymphoma
33%
Mantle Cell Lymphoma
33%
High-risk Cytogenetics
33%
Molecular Abnormalities
33%
Waldenström Macroglobulinemia
33%
Bruton's Tyrosine Kinase
33%
Phosphatidylinositol 3-kinase delta
33%
INIS
patients
100%
toxicity
100%
management
100%
drugs
66%
receptors
66%
malignancies
66%
lymphomas
66%
kinases
66%
diseases
33%
risks
33%
refractories
33%
side effects
33%
recommendations
33%
reviews
33%
tyrosine
33%
leukemia
33%
Medicine and Dentistry
Ibrutinib
100%
Idelalisib
100%
Cancer
66%
B Cell
66%
B Lymphocyte Receptor
66%
Disease
33%
Adverse Event
33%
Side Effect
33%
Elderly Patient
33%
Progression Free Survival
33%
Phosphoinositide 3-Kinase
33%
B-Cell Chronic Lymphocytic Leukemia
33%
Mantle Cell Lymphoma
33%
Follicular Lymphoma
33%
Waldenström's Macroglobulinemia
33%
Bruton Tyrosine Kinase
33%
Pharmacology, Toxicology and Pharmaceutical Science
Idelalisib
100%
Ibrutinib
100%
B Lymphocyte Receptor
66%
Disease
33%
Adverse Event
33%
Side Effect
33%
Progression Free Survival
33%
Follicular Lymphoma
33%
Phosphatidylinositol 3 Kinase
33%
Chronic Lymphatic Leukemia
33%
Bruton Tyrosine Kinase
33%
Waldenstroem macroglobulinemia
33%
Mantle Cell Lymphoma
33%